Загрузка...
Phase I study of TAS-102 and irinotecan combination therapy in Japanese patients with advanced colorectal cancer
Background TAS-102 is a nucleoside antitumor agent consisting of trifluridine (FTD) and tipiracil hydrochloride (TPI). We investigated the recommended dose (RD) of TAS-102 plus irinotecan for metastatic colorectal cancer refractory to 5-fluorouracil (5-FU) and oxaliplatin. Methods This study was use...
Сохранить в:
| Опубликовано в: : | Invest New Drugs |
|---|---|
| Главные авторы: | , , , , , , , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
Springer US
2015
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4768213/ https://ncbi.nlm.nih.gov/pubmed/26163340 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10637-015-0271-1 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|